ACADIA Pharmaceuticals Inc. (ACAD): Today's Featured Drugs Laggard

ACADIA Pharmaceuticals ( ACAD) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole was unchanged today. By the end of trading, ACADIA Pharmaceuticals fell $0.68 (-3.9%) to $16.80 on average volume. Throughout the day, 3,719,388 shares of ACADIA Pharmaceuticals exchanged hands as compared to its average daily volume of 4,354,300 shares. The stock ranged in price between $16.26-$17.85 after having opened the day at $17.65 as compared to the previous trading day's close of $17.48. Other companies within the Drugs industry that declined today were: DARA Biosciences ( DARA), down 10.2%, Infinity Pharmaceuticals ( INFI), down 9.9%, China Pharma ( CPHI), down 9.1% and Rockwell Medical ( RMTI), down 7.3%.

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on small molecule drugs that address unmet medical needs in neurological and related central nervous system disorders. ACADIA Pharmaceuticals has a market cap of $1.6 billion and is part of the health care sector. Shares are up 286.7% year to date as of the close of trading on Monday. Currently there are 9 analysts that rate ACADIA Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates ACADIA Pharmaceuticals as a sell. Among the areas we feel are negative, one of the most important has been weak operating cash flow.

On the positive front, Genvec ( GNVC), up 14.2%, Oncolytics Biotech ( ONCY), up 13.0%, Senesco Technologies ( SNTI), up 11.2% and Peregrine Pharmaceuticals ( PPHM), up 9.6% , were all gainers within the drugs industry with Gilead ( GILD) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.
null

If you liked this article you might like

Biotech M&A: Who's Next After Gilead-Kite?

'Longing' for Acadia Pharmaceuticals? Here's How to Play It

3 Housing Plays With Solid Earnings

7 Potential New Targets for Activist Investor That Made a Killing on Whole Foods

Jana Partners Liquidates Whole Foods Stake After Engineering Industry-Transforming Sale To Amazon